---
schema_version: "secwatch.filing_event.v1"
accession: "0001323885-24-000115"
form_type: "8-K"
ticker: "ATRC"
cik: "0001323885"
company_name: "AtriCure, Inc."
filed_at: "2024-10-29T23:59:59+00:00"
generated_at: "2026-05-30T08:55:51.111945+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# AtriCure Q3 2024: revenue $115.9M (+17.9%), loss $0.17/sh, positive cash flow $16.3M

## Summary
- Worldwide revenue $115.9M, up 17.9% YoY; U.S. $95.5M (+16.8%), Intl $20.5M (+23.3%).
- Net loss per share $0.17 vs $0.20 YoY; adjusted EBITDA $7.9M, up $3.2M from Q3 2023.
- Gross margin 74.9%, down 27 bps YoY due to unfavorable product/geographic mix.
- Generated $16.3M cash flow from operations in the quarter.
- Launched new products; growth driven by open ablation, appendage management, and pain management.

## SEC filing metadata
- accession: 0001323885-24-000115
- form_type: 8-K
- ticker: ATRC
- cik: 0001323885
- company_name: AtriCure, Inc.
- filed_at: 2024-10-29T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1323885/000132388524000115/0001323885-24-000115-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1323885/000132388524000115/atrc-20241029.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001323885-24-000115
- JSON: https://secwatch.observer/filing/0001323885-24-000115.json
- Plain text: https://secwatch.observer/filing/0001323885-24-000115.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.